Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (KNSA) is a clinical and commercial-stage biopharmaceutical company pioneering immune-modulating therapies for autoimmune and cardiovascular diseases. This dedicated news hub provides investors, researchers, and healthcare professionals with timely updates on corporate developments and scientific advancements.
Access the most comprehensive collection of Kiniksa news including regulatory milestones, clinical trial results, and strategic partnerships. Our curated feed delivers essential updates on ARCALYST commercialization progress, abiprubart development phases, and pipeline expansion efforts – all critical for informed decision-making in biopharma investing.
Key content categories cover FDA submissions, research collaborations, financial performance, and therapy access initiatives. The centralized format ensures efficient tracking of Kiniksa's progress in addressing complex inflammatory conditions through targeted immune modulation.
Bookmark this page for streamlined monitoring of KNSA's evolving position in autoimmune therapeutics. Verify information accuracy through direct links to official company communications and peer-reviewed clinical data sources.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced a partnership with NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis. This campaign, starting in September, aims to share experiences from the recurrent pericarditis community and provide resources for patients and caregivers. Recurrent pericarditis is characterized by severe inflammation of the pericardial tissue, leading to sharp chest pain often mistaken for a heart attack. The disease significantly impacts patients' quality of life and physical wellbeing. CEO Sanj K. Patel emphasized the need for increased disease understanding to prevent delayed diagnosis and treatment. More information can be found at whatispericarditis.com and arcalyst.com.
Kiniksa Pharmaceuticals announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative on June 17, 2024. This initiative aims to enhance care for recurrent pericarditis patients through improved diagnosis and treatment practices. The program will involve healthcare champions at 15 sites to identify gaps and share best practices nationwide. The initiative aims to improve patient outcomes and quality of life through education, model sharing, and collaborative research. Key sites involved include Brigham & Women’s Hospital, Cleveland Clinic, and Mayo Clinic.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:40 a.m. Eastern Time.
The presentation will be live-streamed on Kiniksa's website under the Investors & Media section. A replay will be available approximately 48 hours post-event.
Kiniksa Pharmaceuticals, (Nasdaq: KNSA) will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 14, 2024. The presentation will be available via webcast on the company's website.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
